Still Detox provides medically supervised sedative addiction treatment in Boca Raton, Florida. Our board-certified Medical Director manages withdrawal from all sedative, hypnotic, and anxiolytic drug classes — including benzodiazepines, Z-drugs (Ambien, Lunesta), barbiturates, and prescription sleep aids — using CIWA-guided diazepam substitution taper in a private, 14-bed setting adjacent to Boca Regional Hospital. Sedative withdrawal can be fatal without medical supervision. Call now for a same-day assessment.
Free & confidential — takes about 60 seconds
Joint Commission Accredited
Florida DCF Licensed
LegitScript Certified
Psychology Today VerifiedSedative, hypnotic, and anxiolytic use disorder is the DSM-5 classification for addiction to central nervous system depressant medications that act on the GABA-A receptor complex. This drug class includes benzodiazepines, Z-drugs, barbiturates, prescription sleep aids, GHB, and some muscle relaxants. All share a common neurological mechanism: they enhance GABA-A receptor activity, reducing neuronal excitability throughout the CNS. With chronic use, the GABA system downregulates — and when the drug is removed, the rebound neurological hyperexcitability can produce seizures, hallucinations, and cardiovascular instability.
Sedative addiction is distinct from other drug classes precisely because of this withdrawal danger. Unlike opioid withdrawal — which is extremely uncomfortable but rarely directly fatal in healthy adults — sedative withdrawal can kill. The same GABA-A mechanism that makes these drugs effective for anxiety, insomnia, and seizures makes abrupt discontinuation after physical dependence a medical emergency. Still Detox treats the full sedative drug class with CIWA-guided diazepam substitution taper — the clinical standard for safe sedative discontinuation. For benzo-specific content, see our dedicated benzodiazepine addiction treatment page.
All drugs in the sedative, hypnotic, and anxiolytic class act on GABA-A receptors — the brain's primary inhibitory system. With chronic use, receptor sensitivity decreases and receptor density changes as the brain compensates for continuous pharmacological inhibition. When sedatives are abruptly removed, the result is a neurological rebound into intense excitability: the nervous system, accustomed to artificial suppression, fires without restraint. The clinical result can be grand mal seizures, hallucinations, delirium, and cardiovascular instability.
This is why the FDA issued a black box warning on all benzodiazepines in 2020, and why clinical guidelines consistently identify sedative withdrawal as one of the most medically dangerous of all withdrawal syndromes. The risk applies to the full sedative class — not just benzodiazepines. Z-drugs such as zolpidem (Ambien) bind to the same GABA-A receptor and produce the same seizure risk upon abrupt discontinuation, yet are widely perceived as safer because they are marketed differently. This misperception frequently leads to dangerous self-directed discontinuation.
At Still Detox, every sedative client receives a CIWA (Clinical Institute Withdrawal Assessment) assessment at admission to quantify withdrawal severity. The taper protocol — typically using diazepam (Valium) as a substitution agent for its long half-life and clinical controllability — is individualized to the specific sedative, dose, duration of use, and the client's medical history. Vital signs and CIWA scores are monitored throughout the acute taper window.
Sedative withdrawal is medically serious and requires physician-level clinical infrastructure. Still Detox provides the CIWA-guided taper management, hospital-adjacent setting, and dual diagnosis care that the sedative population needs.
Every sedative client receives formal CIWA assessment at admission and throughout the taper window. Diazepam substitution — using Valium's long half-life for a smoother, more controllable taper curve — is the clinical standard for all sedative classes at Still Detox.
Located on the University Hospital campus, adjacent to Boca Regional Hospital. Emergency neurological and cardiovascular services are immediately accessible for any client whose sedative withdrawal escalates to seizure or cardiovascular instability during the taper window.
Private rooms, professional catering, and a calm setting designed to minimize the anxiety rebound and sensory hypersensitivity that characterize sedative withdrawal — managed without the chaos of a hospital ward or the isolation of home taper attempts.
Sedatives are prescribed for anxiety, insomnia, PTSD, and muscle spasm. Still Detox treats the underlying condition concurrently — using non-sedative evidence-based alternatives in the residential program so stopping the sedative does not mean returning to unmanaged anxiety or sleeplessness.
Sedative detox flows directly into inpatient residential treatment on the same campus. The insomnia, anxiety disorder, or PTSD driving sedative use is addressed in the therapeutic program that begins where detox ends — same team, no disruption.
Every team member is fluent in English and Spanish. Service animals (dogs and cats) are welcome. Sedative addiction treatment is available to all adults regardless of language or companion animal status.
People come to Still Detox when a sleeping pill or anxiety medication has become something they cannot stop. Here is what they say about the care and the recovery they found.
The sedative, hypnotic, and anxiolytic class covers multiple drug subgroups that share GABA-A receptor activity but differ in potency, half-life, and clinical withdrawal profile. The timeline and approach differ by subgroup — which is why CIWA assessment at admission is essential before any taper begins.
Benzodiazepines range from short-acting (Xanax, Ativan: onset within 6–12 hours of last dose) to long-acting (Valium, Klonopin: onset 24–72 hours). All carry seizure risk during withdrawal. CIWA-guided diazepam substitution taper is the standard. See our dedicated benzodiazepine addiction treatment page for full drug-by-drug detail and our Ativan treatment page for lorazepam specifically.
Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) are prescribed and perceived as safer non-benzo sleep aids — but they bind selectively to GABA-A receptor subunits and produce the same physical dependence and seizure risk as benzodiazepines. Z-drug withdrawal onset is typically 1–2 days after the last dose. Abrupt discontinuation after nightly use for weeks can produce rebound insomnia, anxiety, tremors, sweating, and seizures. Diazepam substitution taper is indicated for significant Z-drug dependence.
Phenobarbital, butalbital (Fioricet/Fiorinal), and other barbiturates act on GABA-A receptors with a lower therapeutic index than benzodiazepines, making barbiturate withdrawal the most medically dangerous of all sedative withdrawal syndromes. Still Detox manages barbiturate detox with phenobarbital substitution taper and heightened medical monitoring. See our dedicated barbiturates addiction treatment page for full clinical detail.
Carisoprodol (Soma) is metabolized to meprobamate, a barbiturate-like compound with withdrawal seizure risk. Cyclobenzaprine (Flexeril) and methocarbamol (Robaxin) produce milder dependence. GHB and gamma-butyrolactone produce GABA-B agonist dependence with severe, rapid-onset withdrawal. Each requires individual clinical assessment to determine the appropriate taper approach.
Every sedative taper protocol at Still Detox is individualized to the specific drug, dose, duration of use, and clinical history. All sedatives in this class carry medically serious withdrawal risk and require physician-supervised discontinuation.
Benzodiazepines and Z-drugs (non-benzo sleep aids) share GABA-A receptor activity and the same withdrawal seizure risk. CIWA-guided diazepam substitution taper is the protocol for all drugs in this group.
Barbiturates carry the highest mortality risk of any sedative withdrawal. Phenobarbital substitution taper is the protocol. Other sedatives in this group are assessed individually for appropriate taper approach.
Knowing what to expect removes one of the biggest barriers to making the call. Here is how sedative addiction treatment works from first contact through residential care.
Admissions gathers your specific sedative, current dose, duration of use, and co-occurring conditions (anxiety, insomnia, PTSD). PPO benefits verified before you commit. Travel coordinated before arrival.
A call within three days covers your full medication and psychiatric history — so the individualized taper schedule is ready on day one and the Medical Director evaluation begins with a complete clinical picture.
A nurse and behavioral health tech handle intake together. CIWA assessment begins immediately to quantify withdrawal severity. Diazepam substitution and comfort medications are available from the first hours of admission to prevent acute withdrawal from advancing unchecked.
Within 24 hours the Medical Director establishes your individualized diazepam substitution taper schedule — calibrated to your specific sedative, dose, and clinical history. CIWA scores drive taper adjustments daily throughout the acute window.
Vital signs and CIWA assessments guide medication adjustments throughout. Comfort medications address anxiety, insomnia, elevated blood pressure, and nausea. Typical taper stay is 7 to 14 days, longer for high-dose long-duration dependence or barbiturate cases.
After clinical stability is established, you step directly into residential treatment on the same campus. The insomnia, anxiety disorder, or PTSD driving sedative use is addressed using non-sedative evidence-based alternatives — same team, no disruption.
The DSM-5 classifies sedative addiction as sedative, hypnotic, and anxiolytic use disorder using 11 diagnostic criteria. Any 2 or more in a 12-month period constitutes a diagnosis. Mild is 2 to 3; moderate is 4 to 5; severe is 6 or more.
Taking sedatives in larger doses or more frequently than prescribed or planned. Common in individuals whose prescribed dose no longer controls anxiety or insomnia, driving incremental escalation that crosses into physical dependence.
A persistent desire to reduce or stop combined with repeated unsuccessful attempts. The emergence of withdrawal symptoms — anxiety, insomnia, tremors — within hours to days of dose reduction makes self-discontinuation feel neurologically impossible and physically dangerous.
Significant time obtaining sedatives, taking them, or managing their effects — including filling prescriptions early, visiting multiple prescribers, or structuring daily activities around dosing schedules to avoid the onset of withdrawal.
A strong urge to use sedatives, frequently driven by the onset or anticipation of withdrawal symptoms rather than the pursuit of euphoria. In sedative dependence, craving is the nervous system signaling that GABA receptor function is destabilizing.
Sedation, cognitive blunting, anterograde amnesia, and impaired coordination associated with regular sedative use progressively eroding work performance, family responsibilities, and daily functional capacity.
Persisting with sedative use despite conflict with family or partners. Emotional withdrawal, memory impairment, and behavioral changes from chronic sedative use are common interpersonal stressors that escalate with disorder severity.
Giving up hobbies, social engagement, or valued activities in order to use sedatives or to avoid situations where a dose might be missed and withdrawal triggered. Social withdrawal progressively deepens as the disorder advances.
Using sedatives while driving, combining them with alcohol or opioids (dramatically increasing respiratory depression and overdose risk), or using at doses that produce blackouts. The FDA black box warning on benzodiazepines specifically flags the risk of death when combined with opioids.
Persisting despite awareness of cognitive impairment, memory loss, increased fall risk, paradoxical anxiety, depression, respiratory depression, or the documented long-term neurological effects of chronic high-dose sedative use.
Requiring significantly higher sedative doses to achieve the same anxiolytic, sedative, or hypnotic effect, or finding that the prescribed dose no longer provides adequate relief. Tolerance is a direct marker of GABA-A receptor downregulation and advancing physical dependence.
Experiencing rebound anxiety, insomnia, tremors, sweating, elevated heart rate, nausea, sensory hypersensitivity, or seizures when sedatives are delayed or stopped. The presence of withdrawal symptoms is the clearest indicator that medically supervised taper is required — abrupt discontinuation at this point carries seizure and mortality risk.
DSM-5 sedative, hypnotic, and anxiolytic use disorder criteria. If sedatives have become difficult to stop — or if stopping has produced anxiety, tremors, or worse — call now. Do not attempt abrupt discontinuation.
Talk to Admissions ConfidentiallyThese are real before-and-after moments from people who completed treatment at Still Detox and built a life that no longer depends on a sleeping pill or anxiety medication to function.
Sedative withdrawal seizures are documented in individuals using benzodiazepines and Z-drugs at therapeutic doses for extended periods. The risk is higher with short-acting sedatives, abrupt discontinuation, longer duration of use, and prior withdrawal history. Seizure risk cannot be reliably self-assessed without clinical evaluation — the appropriate taper rate requires physician determination.
Rebound anxiety and insomnia during sedative withdrawal routinely surpass the symptoms that originally led to the prescription. The nervous system, accustomed to GABA-A suppression, rebounds into hyperexcitability. For most clients, this makes unsupported discontinuation feel clinically impossible and drives relapse within days of stopping — often in doses higher than the original prescription.
Sedatives are prescribed for anxiety, insomnia, PTSD, muscle spasm, and seizure disorders. Stopping the sedative without treating the underlying condition means those symptoms return in full force during the withdrawal window — at precisely the moment the nervous system is most vulnerable. Dual diagnosis treatment is the clinical center of sedative recovery.
Still Detox is an out-of-network provider for most insurance plans. Many clients with PPO plans that carry out-of-network benefits apply that coverage toward sedative detox and residential treatment. Our admissions team verifies your specific benefits at no cost and with no obligation before admission.
We confirm what your plan covers, walk through any out-of-pocket responsibility, and explain flexible payment options including monthly payment plans and promissory arrangements. Medically necessary sedative detox should never be delayed because of cost.
Don't see your plan? Call us. Our specialists work with many coverage scenarios and will give you an honest answer about what is covered.
Sedative withdrawal produces intense anxiety and sensory hypersensitivity. Our facility is structured, calm, and clinically equipped for the nervous system recalibration that sedative recovery demands.
Sedatives are most commonly prescribed for anxiety. Still Detox treats both the physical sedative dependence and the underlying anxiety disorder concurrently — using non-sedative anxiety management strategies so that stopping the sedative does not mean returning to unmanaged anxiety with no clinical alternative.
Sleeping pills including Ambien, Lunesta, and benzodiazepine sleep aids produce rapid physical dependence with nightly use. Still Detox manages Z-drug and sedative taper alongside evidence-based non-pharmacological insomnia treatment — cognitive behavioral therapy for insomnia (CBT-I) — so that stopping the sleeping pill does not mean returning to sleeplessness.
Extended high-dose sedative use requires a longer, more gradual taper than short-term lower-dose dependence. Still Detox has experience managing complex taper protocols for clients who have been on sedatives for years at high doses — including cases combining benzos with Z-drugs or muscle relaxants — that require clinical precision beyond standard detox protocols.
Sedative withdrawal is a medical emergency waiting to happen without the right clinical support. Our CIWA-guided taper protocols, hospital-adjacent setting, and 24-hour nursing team exist precisely for this population. Same-day assessments are available now. The residential care that addresses what the sedative was treating begins immediately after stabilization.
We're here 24/7. Speak with admissions, confidentially and with no obligation.
✆ Call (561) 556-2677Accreditations & Memberships
We understand that there are no shortcuts on the path to recovery, and our compassionate team offers unwavering support and intensive care throughout your healing journey.
Still Detox is a member of Still Behavioral Health Group.
Get Help Now
If you or someone you care about is seeking support for substance abuse and addiction challenges, we are here to offer our assistance. This is where your journey towards healing begins.
© 2026 | Still Detox Drug and Alcohol Treatment Center in Florida
950 NW 9th CT, Boca Raton, FL 33486
